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The expression and localisation offl-nerve growth factor (f,-NGF) in benign
and malignant human prostate tissue: relationship to neuroendocrine
differentiation
AB Paul, ES Grant and FK Habib
University Department ofSurgery/Urology, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, Scotland, UK.
Summary ,B-NGF is a determinant of sympathetic innervation and a neural differentiation factor. In the
present study, we have examined 15 benign prostatic hyperplastic and 15 prostate cancer patients for the
expression and localisation ofP-NGF by reverse transcription-polymerase chain reaction (RT-PCR), Western
blotting, immunohistochemistry and ELISA. We have correlated the ,B-NGF concentrations to prostate
morphometry and neuroendocrine differentiation. The presence of,NGF mRNA transcripts was confirmed by
RT-PCR where a 542 bp product was found with specific primers for the human f,-NGF cDNA sequence.
The presence of the peptide was also confirmed by Western blot analysis which showed a protein co-migrating
with recombinant human ,B-NGF. Our results demonstrate that ,B-NGF is localised to prostate epithelium, and
the concentrations of the peptide were not significantly different in malignant (mean+s.d.; 3100+ 1502 pg g
wet weight of tissue) than in benign tissues (1992 +684 pg g-, P= 0.512). We were, however, unable to
correlate the concentrations of ,B-NGF to neuroendocrine differentiation in malignant tissues. Clearly, the
present study demonstrates that fl-NGF is a product of the prostate and may be involved in the control of the
sympathetic innervation of the human prostate.
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Beta nerve growth factor (f,-NGF) stimulates the growth of
sympathetic and some sensory neurites; in vitro, NGF was
found to stimulate the growth of dendritic processes from the
undifferentiated PC-12 rat adrenal phaeochromocytoma cell-
line (Tischler and Greene, 1975) while, in vivo, in adult
mammals, tissue NGF concentrations correlated with the
density of tissue sympathetic innervation (Korsching and
Thoenen, 1983). NGF also acts as a positive chemotaxin for
neurones and may facilitate their contact with their target
tissues (Gundersen and Barrett, 1980). NGF production,
therefore, is a means whereby tissues influence the density
and distribution of their sympathetic and sensory innerva-
tion.
Mouse /3-NGF is a homodimer of two protein molecules
of 14.5 kDa each. f,-NGF purified from mouse salivary
glands (the most abundant source of the hormone) is
shortened during purification to a 26.5 kDa dimer known
as 2.5S mNGF (Bradshaw, 1978). Mouse and human f-NGF
show 92% sequence homology and are immunologically
similar, such that antibodies raised against the mouse protein
will recognise the human (Nikolics, 1993; Naher-Noe et al.,
1993). The mouse f3-NGF gene is expressed as a number of
splice variants (Nikolics, 1993). However, only one transcript
of the highly homologous (Ullrich et al., 1983) human gene
has so far been described; this mRNA transcript is spliced
from just two exons. The whole sequence of the mature
hormone is coded in one exon (Borsani et al., 1990). ,B-NGF
dimers are non-covalently bound, and the hormone appears
as a monomeric form under denaturing conditions. Study of
f,-NGF in neoplasia has emphasised its possible role in
tumours derived from the neural crest and in neurogenic
tumours. In the D54 glioma, U118 and U251 glioblastomas,
TE671 medulloblastoma and Hs294 melanoma cell lines, /B-
NGF treatment leads to variable differentiation of these cells
with a reduction in growth rates (Yaeger et al., 1991). All of
these cell lines bear /3-NGF receptors, with melanoma cell
lines having a particularly high concentration of these
receptors (Buxser et al., 1984). The capacity of ,B-NGF to
inhibit growth of neurogenic tumours is supported by the in
vivo finding that neuroblastomas which express high-affinity
f,-NGF receptors have a better prognosis than those which
do not (Kogner et al., 1993).
In spite of the role of adrenergic innervation in outflow
tract obstruction (Lepor and Shapiro, 1990) and recent
interest in prostate neuroendocrine cells as a prognosticator
in prostate adenocarcinomas (Cohen et al., 1991), ,B-NGF has
received little attention in the human prostate. In the
prostates of rodents, it may be present in high concentration
and is localised to prostate epithelium (Harper and Thoenen,
1980; Shikata et al., 1984; MacGrogan et al., 1990). Recently,
MacGrogan et al. have found f,-NGF expression and variable
,B-NGF concentrations (0-1720 pg g-') in human benign
hyperplastic (BPH) tissue (MacGrogan et al., 1992).
Furthermore, Djakiew's group have localised f,-NGF to the
stroma of the human gland by immunohistochemistry
(Graham et al., 1992) - a surprising result in view of the
high degree of conservation of the hormone and its epithelial
localisation in other mammals. In cell culture studies, this
group have demonstrated that proteins produced by prostate
stromal and epithelial cells that are immunologically related
to, but heavier than, /3-NGF (42-65 kDa), stimulate the
growth of both stromal and epithelial cells in culture
(Djakiew et al., 1991).
The aims of this study were to examine the expression of
fl-NGF in benign hyperplastic and malignant human prostate
tissue at the protein and mRNA levels. f3-NGF concentration
and neuroendocrine cell content of prostate adenocarcinomas
were also compared.
Materials and methods
Tissues
Transurethral resection of the prostate (TURP) 'chips' were
obtained from 15 cases each of BPH and prostate cancer. For
control studies, an adrenal gland was obtained from an organ
donor (aged 15 years) after familial consent. Tissues were
snap-frozen in liquid nitrogen and stored at -70°C.
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Randomly selected prostate chips from prostate adenocarci-
noma specimens were examined histopathologically and
tumour grade assessed by Gleason scoring. Paraffin-
embedded tissue from the 15 prostate adenocarcinomas was
obtained. Paraffin-embedded autopsy pancreas tissue was also
obtained and islets of Langerhans used as a positive control
for neuroendocrine stains.
Reverse transcription-polymerase chain reaction (RT-PCR)
for f3-NGF
Total cellular RNA was prepared from prostate tissues by the
method of Chomczynski and Sacchi (1987). Briefly, 5 jig of
sample RNA were reverse transcribed by the addition of
20 jil of 25 mm magnesium chloride, 10 Mil of transcriptase
buffer, 10 jil of 10 mM dNTP mixture, 100 U RNAsin, 2.5 jil
of oligo (dT) and 67.5 U AMV reverse transcriptase
('Reverse transcription system' kit, Promega Corporation,
Southampton, UK). The mixture was incubated for 1 h at
42°C. f,-NGF primer sequences were 5'-GACCCAAGCT-
CAGCTCAGC-3' and 3'-TATTCTGGTGGCGGTGTCTG-
5', defining a 542 bp fragment designed from the human /3-
NGF cDNA sequence (Borsani et al., 1990). PCR amplifica-
tion was carried out in a volume containing 20 jil of the RT
product mixture, 8 jil of Taq polymerase buffer, 10 jl of 5'
and 3' primers, 16 jil of 1.25 mM dNTP mixture and 0.2 ,ul of
Taq polymerase (Promega 'Taq polymerase' kit). Reaction
mixtures underwent denaturation at 94°C for 90 s, annealing
at 58°C for 90 s and extension at 72°C for 150 s for 35 cycles
using a Hybaid 'Thermal Cycler' (Hybaid, Teddington, UK).
As a positive control, RNA isolated from adrenal tissue was
subjected to RT -PCR amplification in the same way as
prostatic RNA. Dral, EcoRI and PstI (Promega) digests were
carried out at 37°C for 1 h in 35 jil volumes containing 20 pl
of PCR product, 2.5 pl of endonuclease buffer, 2.5 jil of
acetylated bovine serum albumin (BSA), 9.5 jil of ultrapure
water and 0.5 jil of the endonuclease. RT-PCR products,
endonuclease digests and a 100 bp molecular weight ladder
were size fractionated and visualised by electrophoresis on
1% (w/v) agarose, 1 x TBE gels with ethidium bromide.
Western blot analysis of j3-NGF-like immunoreactivity in
prostate tissue
Protein electrophoresis was after Laemmli (1970). Prostate
tissue was powdered and homogenised in a solution
containing 0.1 M sodium chloride, 0.01 M tris-HCl, 0.001 M
EDTA, 1 pg ml-' aprotinin and 100 pg ml-' phenylmethyl-
sulphonyl fluoride (PMSF) (pH 7.6). The homogenates were
subsequently diluted 1: 1 (v/v) in denaturing buffer [100 mM
tris-HCl, 200 mM dithiothreitol (DTT) 4% (w/v) sodium
dodecyl sulphate (SDS), 0.2% (w/v) bromophenol blue and
20% (w/v) glycerol], boiled for 10 min, sonicated for 1 min
('Soniprep-150', Sanyo-Gallenkamp, Leicester, UK) and
centrifuged at 14 000 g for 10 min. The protein concentra-
tion of the supernatant was assayed using the Bradford
(1976) method.
Aliquots of 300 jig of prostate protein and 5, 10 and 50 ng
rh,B-NGF standards along with 20 ,ul of 'Rainbow' molecular
weight markers (Amersham International, Amersham, UK),
were electrophoresed at 20 mA in the stacking gel (5%
polyacrylamide, 187.5 mM Tris, 0.1% SDS, 0.1% ammonium
sulphate) and 40 mA in the resolving gel (15% polyacryla-
mide, 375 mM Tris, 0.1% SDS, 0.1% ammonium sulphate),
using Tris-glycine as a running buffer (25 mM tris-HCl,
575 mM glycerine, 0.1% (w/v) SDS). The gels were
equilibrated in transfer buffer [48 mM tris base, 39 mM
glycine, 20% (v/v) methanol and 0.0375% (w/v) SDS] and
blotted overnight onto nitrocellulose membranes ('Hybond-
C', Amersham International) using a Biorad 'Trans-blot'
semi-dry apparatus. The membranes were washed in TNF
(50 mM tris base, 150 mm sodium chloride, 2 mM EDTA)
and blocked in the same solution with 2% (w/v) BSA and
5% (w/v) semi-skimmed dried milk for 2 h at room
temperature. The membranes were then incubated for 1 h
in the blocking solution with 1:1000 polyvalent rabbit anti-
2.5S mNGF. Bound primary antibody was detected by
incubation in the blocking solution with 1:1000 horseradish
peroxidase-conjugated whole donkey anti-rabbit IgG for 1 h
at room temperature. Antibody detection was performed with
the enhanced chemoluminescence (ECL), Western blotting
analysis system (Amersham).
Immunohistochemical staining for f,-NGF and neuroendocrine
cells
Frozen sections of prostate tissue and adrenal gland (7-
8 jim) were cut, fixed in methanol (4°C, 3 min) and stained
for f,-NGF. The ,B-NGF primary antibody was polyvalent
rabbit anti-2.5S mNGF (Universal Biologicals, London, UK)
diluted 1:100 in Tri-buffered saline (TBS) with 3.5% bovine
serum albumin (BSA) and 0.1% sodium azide (TBS/BSA/
azide). For neuroendocrine cell staining 4 gm sections of the
paraffin-embedded malignant prostate and autopsy pancreas
tissues were used. The primary antibody was polyvalent
rabbit anti-human PGP9.5 (Ultraclone, Isle of Wight, UK;
1: 400 in TBS/BSA/azide).
Briefly, slides were incubated in 20% normal sheep serum
(Scottish Antibody Production Unit, Carluke, UK) in TBS for
30 min before exposure to the primary antibody for 30 min.
After a TBS wash, sections were subsequently incubated with a
secondary sheep anti-rabbit IgG biotinylated F(ab')2 fragment
(Boehringer Mannheim Biochemica, Lewes, UK), at a dilution
of 1: 400 in TBS/BSA/azide for 30 min. After a further TBS
wash, slides were incubated with streptavidin-linked alkaline
phosphatase ('extravidin', Sigma, 1:1000 in TBS/BSA/azide)
for 30 min. The substrate colour reaction was developed with
fuchsin chromogen solution ('New Fuchsin', Dako, High
Wycombe, UK) for 15 min before counterstaining with
Mayer's haematoxylin for 1 min. Slides were air-dried and
mounted with DPX medium and cover-slips. The adrenal and
pancreatic tissues provided positive controls for f3-NGF and
PGP9.5 staining, respectively, while negative controls were
carried out with the omission ofthe primary antisera from the
TBS/BSA/azide preparation.
Sections were examined for positive staining for ,B-NGF
and PGP9.5 by an independent pathologist. Tumours were
simply classified as positive or negative for PGF9.5.
Enzyme-linked immunosorbent assay (ELISA)
The concentration off,-NGF in prostate tissues from patients
with BPH and prostate cancer was measured as follows:
230-550 mg of frozen prostate tissue was pulverised in a
'mikrodismembrator', (Braun Medical, Aylesbury, UK) and
the powdered tissue was suspended in 500 jil of 100 mM tris-
HCI containing 400 mm sodium chloride, 2% (w/v) BSA,
0.1% (w/v) sodium azide, 4 mM EDTA, 1 mM phenylmethyl-
sulphonyl fluoride (PMSF) and 7 ug ml-' aprotinin and
homogenised with an 'Ystrall' homogeniser (Ystrall GmbH,
Dottingen, Germany). For recovery, 500 c.p.m. of [1251]2.5S
mNGF 1500 Ci mmol-1 (NEN, DuPont, Stevenage, UK)
were added to each homogenate and allowed to equilibrate
for 2 h at 40C, following which homogenates were
ultracentrifuged at 100 000 g for 10 min. Gamma emissions
from the supernatant and pellet were counted and the
recovery fraction for NGF assessed - c.p.m.supernatant!
C.p.m.supematant+pellet. Supernatants were diluted 1: 1 with a
solution containing 20 mm calcium chloride and 0.2% (w/v)
Triton X-100. Aliquots of 100 jil were incubated along with
rh#-NGF (Boehringer Mannheim) standards (0-
315 pg ml-') in microtitre plates ('Maxisorp', Nunc, Kamstr-
up, Denmark), coated with 0.4 jig ml-' mouse monoclonal
anti-mouse #-(2.5S, 7S) NGF (Boehringer Mannheim) in
triplicate for 16 h at 4°C. This was followed by an incubation
with a second-antibody mouse monoclonal anti-mouse 1l-
(2.5S, 7S) NGF-fl-galactosidase (Boehringer Mannheim) at
1: 9 dilution for 2 h at 37°C. The substrate colour reaction
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was developed with 2 mg ml-' chlorophenol red-j3-D-
galactopyranoside at 37°C for 2-4 h. The AA540 nm was
measured on a Biorad '450 microplate reader' (Biorad,
Hercules, CA, USA).
Tissue morphometry
Frozen sections were cut from a portion ofeach prostate chip
subject to ELISA. After haematoxylin and eosin staining,
these sections were used for tissue morphometry. Sections
were examined with a microscope attached to an Olympus
'CCD' camera and Olympus 'Cue-2' (Olympus Optical,
Tokyo, Japan), image analysis software. The entire area of
the sections was analysed to avoid problems of random
sample selection in tissue. The total area of each tissue
section and the area of its contained acini and ducts were
measured - referred to here as the 'glandular' area.
To ensure that the frozen sections accurately reflected the
relative portions of glandular and stromal tissues in the
assayed tissue, they were taken immediately adjacent to the
assayed tissue itself. The small size ofprostate tissue fragments
provided by TURP precluded taking a number of frozen
sections through the assayed tissue. It was assumed that areas
of tissue components measured on a tissue section reflect the
underlying volumes of those tissue components in the tissue
studied. Furthermore, it was assumed that the relative
volumes of tissue components accurately reflects the relative
weights of those tissue components. These assumptions have
been verified by Rohr et al. (1976). Thereby, as the weight of
each prostate chip used in ELISA was known, the percentage
volume of 'glandular' tissue (i.e. prostate ducts and acini) and
its weight could be calculated in each ELISA sample.
The correlation (Pearson) between % volume of
'glandular' tissue and f3-NGF concentration was calculated.
The ELISA results were recalculated as pg fl-NGF 100 mg-'
'glandular' tissue.
Statistics
Statistical comparisons were obtained using the Mann-
Whitney rank sum test and Pearson's linear regression
('Minitab 8.0c.', Minitab, PA, USA).
Results
Reverse transcription-polymerase chain reaction for /'-NGF
mRNA
The presence offl-NGF gene transcripts in BPH and prostate
cancer tissue was examined by PCR amplification after
reverse transcription of total RNA from three BPH and three
prostate cancers. A 542 bp amplification fragment indicating
the presence of fl-NGF mRNA was seen in the positive
control adrenal specimen and all prostate specimens (Figure
1).
The RT-PCR protocol did not allow quantitation of the
fl-NGF mRNA present, however, endonuclease digests
confirmed the identity of the amplified fragment. DraI
generated fragments of 224 and 318, EcoRI of 59 and 483
and PstI of 163, 168 and 210.
Detection offl-NGF protein by Western blotting
Protein extracted from three BPH tissues and three prostate
cancers were analysed by Western blot for the presence of ,B-
NGF. The prostate specimens with the highest fl-NGF
concentrations, as measured by ELISA, were used for
Western blotting. A single protein band was found in all
the specimens analysed which co-migrated with a sample of
positive control rh,B-NGF (Figure 2). Like the RT-PCR, the
Western blots were not quantitative. In gels not shown, the
protein band found in prostate tissue was run sufficiently far
into the resolving gel to exclude the presence of heavy, NGF-
like proteins (45 kDa or heavier).
Immunohistochemical staining
f3-NGF In BPH tissue specimens (n= 15, i.e. 15 patients),
specific and intense staining for ,B-NGF was confined to the
epithelium with only occasional stromal cells showing faint
staining (Figure 3). Staining was most intense at the apical
border of prostate epithelium (Figure 4). In cancer tissue
(n = 15), staining was also confined to epithelium of
adenocarcinomas while surrounding stroma was not stained
(Figure 5). Positive staining for ,B-NGF was seen in the
adrenal gland controls, and no staining was seen in the
negative controls (not shown).
Neuroendocrine cells (PGP9.5) Fifteen prostate cancer
specimens were examined for PGP9.5 staining. Positive
staining in adenocarcinomas varied from sparse focal groups
of cells to a widespread staining as shown in Figure 6.
Tumours, however, were simply classified as positive or
negative and, of the 15 specimens examined, seven tumours
were PGP9.5 positive and eight were PGP9.5 negative. All
pancreatic positive control tissues showed staining in cells of
the islets of Langerhans, while negative controls showed no
staining.
f3-NGF concentrations in prostate tissues
The concentrations of fl-NGF in 15 adenocarcinomatous and
15 BPH specimens were measured using an ELISA assay.
The detection limit of the assay was 5 pg ml-1 and the
recoveries varied between 27% and 51% (mean+
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Figure 1 A composite photograph of resolving gels (1% agarose,
1 x TBE, ethidium bromide) of RT-PCR products. Lane 1
contains the 100bp ladder. Lane 2 contains a positive control
amplification of hypoxanthine reductase mRNA. Amplifications
from BPH tissue are in lanes 3, 4 and 5; adenocarcinomas in lanes
6, 7 and 8. Lane 9 contains the positive control adrenal
amplification product. In all the tissues examined, the presence
of f,-NGF mRNA is demonstrated by the presence of the
expected amplification product of 542bp.
1 2 3 4 5 6 7
NGF-
Figure 2 A composite photograph of Western blots. Lane 1
contains lOng positive control rh_-NGF. Lanes 2, 3 and 4
contain 300gg each of protein prepared from BPH tissue. Lanes
5, 6 and 7 contain 300,ug each of protein prepared from
adenocarcinoma tissue. Protein was detected with polyclonal
rabbit anti-mouse 2.5S NGF primary antibody. All prostate
tissues showed the indicated protein band which co-migrated with
recombinant human fl-NGF.
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Figure 3 Benign hyperplastic tissue stained with polyclonal Figure 5 Prostate adenocarcinoma (original magnification x 32)
rabbit anti-mouse 2.5S NGF serum (original magnification stained for ,B-NGF. The tumour is infiltrating from the upper
x 32; positive staining, black). Specific staining is seen to be right hand corner of the field into an area of stroma. Positive
confined to the glandular epithelium and is most marked towards staining is largely confined to the epithelial cells of this
its luminal aspect. moderately well-differentiated area of tumour. There is little
staining of cells in the stroma.
Figure 4 Higher power view (original magnification x 128) of a Figure 6 Prostate adenocarcinoma stained with polyclonal rabbit
benign prostate epithelium stained for ,B-NGF (black). The basal anti-human PGP9.5 serum (original magnification x 12). Wide-
epithelial cells show occasional staining but staining is most spread areas ofpositive (black) PGP9.5 staining are seen. Staining
pronounced along the luminal aspect of the secretory layer cells. of neural bundles is also apparent.
The underlying stroma is not stained.
s.d. = 33.9+4.879). The distribution off3-NGF concentrations
as expressed per gram wet weight of tissue in BPH and
prostate cancer is detailed in Figure 7. The mean+s.d.
concentration in BPH tissue (1992+684 pg g-') was
lower than the concentration in prostate cancer
(3100+ 1503 pg g-') but, because of the significant overlap
in the two groups, the difference was not significant
(P=0.512). Furthermore, there was no significant correla-
tion between the ,B-NGF concentrations in adenocarcinoma
and Gleason score.
Tissue morphometry and the interpretation of ELISA results
with morphometric data
The contribution of 'glandular' tissue to total volume was less
in BPH (n=15, 0-26%, x=13.9%, s.d.=7.88) than in
adenocarcinoma (n= 15, 7-66%, x=35.1, s.d.=20.27). In
BPH and adenocarcinoma, the contribution of 'glandular'
tissue to assayed volume and the ,B-NGF concentration
correlated significantly (Pearson, Figure 8).
One BPH specimen contained stromal tissue only. That
specimen was excluded. For the other BPH and cancer
tissues, the fl-NGF concentration was recalculated as
pg 100 mg-' 'glandular' tissue. The concentration so
expressed was significantly higher in BPH tissue (n = 14,
mean = 1597 pg 100 mg-', s.d. =788) than in adenocarcino-
ma (n= 15, mean= 1058 pg 100 mg-1, s.d.=559, P=0.0195;
Figure 9).
The relationship between f,-NGF concentrations and PGP9.5
staining in prostate cancer
The P-NGF concentrations in prostate cancer were correlated
to the PGP9.5 staining patterns but there was no difference
found between PGP9.5 positive (n= 7; mean ,B-NGF
concentration 3238 pg g-') and the PGP9.5 negative (n=8;
mean ,B-NGF concentration 2982 pg g-') groups (P=0.773).
Similarly, after correction for morphometric data, there was
no significant difference between the two groups (PGP9.5
positive, mean = 1141 pg 100 mg 1; PGP9.5 negative,
mean= 959 pg 100 mg-', P=0.452).
Discussion
The data presented in this study demonstrated the
immunohistochemical localisation of JJ-NGF to the epithelial
elements in prostate tissue. This contrasts to earlier studies
showing that fJ-NGF localised to the prostate stroma. While
both studies employed the same primary fl-NGF antiserum,
there were differences in the techniques employed with regard
to blocking agents. The earlier report by Graham et al. (1993)
used ovalbumin with a goat secondary antibody, whereas, in
the present study, we employed 20% sheep serum along with
a sheep secondary antibody. Whether this would account for
the differences seen is not clear, but it is well established that
the use of blocking and secondary sera from the same species
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Figure 7 A scattergram of fl-NGF concentration measured by
ELISA. Concentration is expressed as pgg-l wet weight of
prostate tissue. The bars show mean concentrations in the two
groups of tissue assayed.
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Figure 9 Scattergram of ,B-NGF concentration in 14 BPH
samples and 15 prostate cancer tissues, measured by ELISA
and expressed as pg 100mg-1 of glandular tissue as measured by
video-image analysis. The bars show the mean values in the two
groups. After correction for the content of glandular tissue the
position seen in Figure 7 is reversed. That is, BPH glandular
tissue contains more ,B-NGF than does prostate cancer tissue.
produces less non-specific staining (Bancroft and Cook,
1994). This, however, does not explain the failure by
* Graham et al. (1992) to stain the epithelium in their prostate
specimens. Significantly, however, f-NGF is a highly
conserved protein, and in support of our findings are
previous studies demonstrating that fJ-NGF is localised to
)o - *- > @prostate epithelium in other species (Harper and Thoenen,
1980; Shikata et al., 1984; MacGrogan et al., 1990). In
addition, in the case of prostate adenocarcinoma, such
epithelial staining has been previously described by
DeSchryver-Kecskemeti et al. (1987), who localised ,B-NGF
to epithelial elements of five human prostatic adenocarcino-
0 mas by immunohistochemistry. The localisation of f-NGF to
0 10 20 30 the epithelium in humans is in keeping with these findings. In
Volume of glandulartissue (%) spite
of the low abundance of ,B-NGF
in these tissues, this
study, like those cited, demonstrated intense ,B-NGF staining
in the prostatic epithelia studied.
0o - The concentrations of fl-NGF found in the human
prostate (905-5887 pg g-1 wet weight of tissue) were high
in comparison to other previously studied human tissues.
MacGrogan et al. (1992), however, found up to 1720 pg g-'
)o * *in BPH tissues. In their studies, fl-NGF recovery from tissue
homogenates was not measured, and the control protein used
0 _ Wwas mouse 2.5S NGF. The measurement of recovery with
[1251]2.5S mNGF, and the use of rh,B-NGF as the control
so / )
explain higher ,B-NGF
concentrations found
The comparison of f3-NGF concentrations expressed as
0 pg g-' wet weight of tissue and as pg 100 mg-' of 'glandular'
tissue was illuminating. P-NGF concentrations in adenocar-
cinoma were higher than those in benign tissues. However,
0 after ,B-NGF concentrations were expressed in terms of o 10 20 30 40 50 60 70 the assayed tissue's 'glandular' content, it was clear
Volume of glandular tissue ( that malignant epithelial tissue contained less P-NGF
(mean= 1058 pg 100 mg-') than benign epithelium
The relationship between the percentage volume of g1,
tissue and fl-NGF concentration (pgg-1 wet weight of (mean = 1597 pg I00 mgi-t , Pw= 0.0a1a95). Hence, the malig-
BPH (top) and prostate adenocarcinoma (bottom) nant state iS associated with a relative loss of p-NGF by the
he lines are of linear regression (Pearson). In both prostate epithelium in spite of the hormone's higher
here are moderately strong and highly significant concentration in tissue. The morphometric analysis here
ns (BPH r=0.67, P=0.006; adenocarcinoma r=0.70, was tedious and subject to sampling error. Nonetheless, it
1. had a major impact on the interpretation of ELISA results. It
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is suggested that the interpretation of many differences in
biochemistry of benign and malignant prostate tissues would
be affected by the use of morphometric data.
The original report of Cohen et al. (1991) that
neuroendocrine differentiation was a powerful prognostica-
tor in prostate adenocarcinoma has not been supported by
other authors (Allen et al., 1995). Although the presence of
these cells may not be a prognosticator, there is evidence that
as prostate adenocarcinomas dedifferentiate (Allen et al.,
1995), progress (Aprikian et al., 1994) and become androgen
independent (Berner et al., 1993), they contain a higher
portion of neuroendocrine elements. It is also clear that these
cells do not bear androgen receptors in normal hyperplastic
or adenocarcinomatous prostate tissues (Iwamura et al.,
1994; Bonkhoff et al., 1993) and that some of their secreted
products may be growth promoting for prostate epithelial
cells (Power et al., 1991; Pinski et al., 1993). Therefore, it can
be postulated that androgen depletion therapies confer a
survival advantage to neuroendocrine cells over other
prostate cancer cells and that neuroendocrine cells may then
promote androgen-independent prostate cancer growth (di
Sant-Agnese, 1995).
Because of local experience in staining bronchogenic
carcinomas for neuroendocrine elements with antibodies
against PGP9.5, that antibody was used to stain neuroendo-
crine cells in prostate tissue. As far as we are aware, this is
the first report of such a use of this antibody. PGP9.5 is a
25 kDa hydrolase which is specifically associated with neural
and neuroendocrine cells (Wilson et al., 1988) and which is
responsible in those cells for the C-terminal hydrolysis-
activation of ubiquitin (Jentsch, 1992).
The proportion of adenocarcinomas showing PGP9.5
staining in the present study was 46.7%, and this was
similar to the figure found by di Sant-Agnese and Jensen
(1987), using the argyrophil reaction and a battery of
immunohistochemical stains (47%). Interestingly, we were
unable to detect any correlation between the concentration of
the neural differentiation factor f,-NGF and the presence of
neural differentiation, as demonstrated by positive PGP9.5
staining.
Western blot analysis of prostate proteins with the primary
antiserum used in immunohistochemistry identified a single
protein band which co-migrated with a sample of rh,B-NGF.
Earlier studies by Djakiew et al. (1991) have also described
heavier NGF-like protein products (42-65 kDa) from
prostate cell cultures, but there was no evidence of these
heavy NGF-like proteins in the human prostate tissues
analysed here. NGF-like proteins in the human prostate
represent fl-NGF itself, while heavier NGF-like proteins were
not detected in native human tissue.
fl-NGF in peripheral tissues has predominantly been
regarded as a determinant of sympathetic and sensory
innervation. Recent studies have demonstrated that, in
addition, NGF is involved in the paracrine control of
prostate epithelial growth through the production of NGF
by prostate stroma (Graham et al., 1992); these act
mitogenically via specific receptors on the epithelium
(Djakiew et al., 1991).
However, our own data do not support this view as we
have immunohistochemically localised ,B-NGF to prostate
epithelium and confirmed this by demonstrating the presence
of a positive correlation between f,-NGF concentration and
the epithelial content of prostate tissue. Malignant prostate
epithelia contain less ,B-NGF than do benign epithelia, but
the concentration of /3-NGF in malignant tissue, as a whole,
is higher than that in benign tissue.
The data presented here suggest that fl-NGF is an
endogenous product of the prostate gland and f,-NGF
concentrations present in the gland (1-6 ng g-') are similar
to concentrations causing neuronal differentiation and growth
in vivo (Tischler and Greene, 1975).
Graham et al. (1992) and MacGrogan et al. (1992) have
localised the low-affinity nerve growth factor to the prostatic
epithelium, in keeping with the view that f,-NGF acts upon
those cells. As fl-NGF also stimulates the growth of
sympathetic neurones, we postulate that, by producing
,B-NGF, prostate epithelium may recruit sympathetic
nerves - and hence smooth muscle. That is, that f,-NGF
may be one mediator of the stromal-epithelial relationship,
produced by the epithelium and acting upon the stroma
(Tenniswood, 1986).
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